2s exciton-polariton revealed in an external magnetic field

We demonstrate the existence of the excited state of an exciton-polariton in a semiconductor microcavity. The strong coupling of the quantum well heavy-hole exciton in an excited 2s state to the cavity photon is observed in non-zero magnetic field due to surprisingly fast increase of Rabi energy of the 2s exciton-polariton in magnetic field. This effect is explained by a strong modification of the wave-function of the relative electron-hole motion for the 2s exciton state.Comment: 5 pages, 5 figure

Magnetic field tuning of exciton-polaritons in a semiconductor microcavity

We detail the influence of a magnetic field on exciton-polaritons inside a semiconductor microcavity. Magnetic field can be used as a tuning parameter for exciton and photon resonances. We discuss the change of the exciton energy, the oscillator strength, and redistribution of the polariton density along the dispersion curves due to the magnetically induced detuning. We have observed that field-induced shrinkage of the exciton wave function has a direct influence not only on the exciton oscillator strength, which is observed to increase with the magnetic field, but also on the polariton linewidth. We discuss the effect of the Zeeman splitting on polaritons the magnitude of which changes with the exciton Hopfield coefficient and can be modeled by independent coupling of the two spin components of excitons with cavity photons

Multi-Target Approach for Drug Discovery against Schizophrenia

Polypharmacology is nowadays considered an increasingly crucial aspect in discovering new drugs as a number of original single-target drugs have been performing far behind expectations during the last ten years. In this scenario, multi-target drugs are a promising approach against polygenic diseases with complex pathomechanisms such as schizophrenia. Indeed, second generation or atypical antipsychotics target a number of aminergic G protein-coupled receptors (GPCRs) simultaneously. Novel strategies in drug design and discovery against schizophrenia focus on targets beyond the dopaminergic hypothesis of the disease and even beyond the monoamine GPCRs. In particular these approaches concern proteins involved in glutamatergic and cholinergic neurotransmission, challenging the concept of antipsychotic activity without dopamine D2 receptor involvement. Potentially interesting compounds include ligands interacting with glycine modulatory binding pocket on N-methyl-d-aspartate (NMDA) receptors, positive allosteric modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, positive allosteric modulators of metabotropic glutamatergic receptors, agonists and positive allosteric modulators of α7 nicotinic receptors, as well as muscarinic receptor agonists. In this review we discuss classical and novel drug targets for schizophrenia, cover benefits and limitations of current strategies to design multi-target drugs and show examples of multi-target ligands as antipsychotics, including marketed drugs, substances in clinical trials, and other investigational compounds